University Of Michigan Rogel Cancer Center

This study tests two drugs, pembrolizumab and lenvatinib, in 45 people with advanced neuroendocrine prostate cancer that has spread. The goal is to see if the combination can slow tumor growth. Treatment continues until the cancer worsens or side effects become too severe, for up…

This study tests a treatment plan for men with prostate cancer that has spread to a few other parts of the body (oligometastatic). The treatment combines focused radiation with a hormone therapy (ADT), a drug called abiraterone, and a targeted drug called Lynparza (olaparib). The…

This study tests a personalized radiation approach for people with advanced HPV-related throat cancer that is at high risk of coming back. About 19 participants will receive radiation boosted to the exact tumor shape using special scans, aiming to keep the cancer under control wh…

This study tests a powerful mix of treatments—hormone therapy, a targeted drug called niraparib, and precise radiation—for men with aggressive or lymph node-positive prostate cancer. The goal is to find the safest dose and see if this approach can keep cancer from coming back for…

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This study tests a new drug called APG-115, alone or with chemotherapy, in people with a specific type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults wit…

This study tests whether giving a higher, targeted dose of radiation to the most aggressive parts of a glioblastoma brain tumor can help people live longer. The radiation plan is adjusted during treatment based on MRI scans. The trial includes 30 adults with newly diagnosed gliob…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive MMF alongside radiation. The m…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide if it's safe to monitor their cancer closely instead of treating it right away. About 800 men with early-stage prostate cancer are taking part. The goal is to see if the test helps m…

This study tests whether combining two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combi…

This study tests whether an 8-week virtual music-based relaxation program can help reduce anxiety in teens and young adults who have finished cancer treatment. About 50 participants aged 15-39 with anxiety will take part. The program involves 45 minutes of tailored music relaxati…

This study looks at whether certain older women with a specific type of early-stage breast cancer can skip radiation after a lumpectomy. The 202 participants are all postmenopausal, have hormone-positive, HER2-negative tumors, and plan to take hormone therapy. Researchers will fo…